Only in Titles

Search results for: AFP Antibody

paperclip

#33955434   2021/05/06 To Up

Lowly-aggregated perylene diimide as a near-infrared electrochemiluminescence luminophore for ultrasensitive immunosensors at low potentials.

In the electrochemiluminescence (ECL) field, most reported luminophores were focused on high-triggering potential and short wavelength, which was adverse for the ECL theory study and application at low potentials. Perylene diimide derivatives could emit near-infrared (NIR) ECL at low-triggering potential; however, they are always highly aggregated into a microrod structure and stacked together, which largely limited their application in biological fields such as bio-sensing and bio-imaging. To overcome these obstacles, we designed a novel perylene diimide molecule, namely N,N'-dicaproate sodium-3,4,9,10-perylenedicarboximide (PDI-COONa). This molecule self-assembled into a two-dimensional network nanostructure, which largely decreased the aggregation degree of PDI molecules and provided solid bases for designing lowly-aggregated PDI molecules. Also, the formed nanoluminophore produced strong emission at -0.26 V with an NIR wavelength 700 nm, which should be due to the excited J-type PDI-COO- dimers. Moreover, this network nanoluminophore well-dispersed on graphene oxide (GO) as an ECL nanomaterial to label secondary antibodies and fabricate a sandwiched immunosensor for alpha-fetoprotein (AFP) detection between 0 and -0.6 V. This immunosensor showed a wider linear response for AFP ranging from 0.1 fg mL-1 to 1 μg mL-1 with a low detection limit 0.0353 fg mL-1 compared with other immunosensors based on PDI microrod-modified GO ECL materials. The fabricated immunosensor also showed good feasibility in human serum samples.
Yunyun Wang, Yanmo Li, Wei Zhang, Peng Yin, Lei Shang, Rongna Ma, Liping Jia, Qingwang Xue, Shuijian He, Huaisheng Wang

1207 related Products with: Lowly-aggregated perylene diimide as a near-infrared electrochemiluminescence luminophore for ultrasensitive immunosensors at low potentials.

50 assays200 assays1 kit1000 assays100Tests2001000 assays100 tests1000 assays200 assays

Related Pathways

paperclip

Error loading info... Pleas try again later.
paperclip

Error loading info... Pleas try again later.
paperclip

#33822328   2021/04/06 To Up

Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison.

Cabozantinib and ramucirumab are approved for the treatment of adults with hepatocellular carcinoma (HCC) following prior sorafenib treatment; ramucirumab is restricted to use in patients with serum alpha-fetoprotein (AFP) ≥ 400 ng/mL. This matching-adjusted indirect comparison evaluated the efficacy and safety of both drugs after sorafenib in patients with HCC and AFP ≥ 400 ng/mL.
Jörg Trojan, Patrick Mollon, Bruno Daniele, Florence Marteau, Lidia Martín, Yuxin Li, Qing Xu, Fabio Piscaglia, Renata Zaucha, Debashis Sarker, Ho Yeong Lim, Marino Venerito

2515 related Products with: Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison.

5 G1000 tests100.00 ul1000 TESTS/0.65ml100ug Lyophilized1 g100ul1 ml10 mg1mg

Related Pathways

paperclip

#33813432   // To Up

Efficacy of Ramucirumab Sorafenib as Subsequent Treatment for Hepatocellular Carcinoma.

The present study aimed to examine the therapeutic efficacy of ramucirumab compared with that of sorafenib as subsequent systemic therapy for patients with hepatocellular carcinoma (HCC) and serum α-fetoprotein (AFP) levels ≥400 ng/ml.
Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, Yuki Tahata, Kazuyoshi Ohkawa, Masahide Oshita, Shinji Tamura, Hideki Hagiwara, Eiji Mita, Takayuki Yakushijin, Masami Inada, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara

1132 related Products with: Efficacy of Ramucirumab Sorafenib as Subsequent Treatment for Hepatocellular Carcinoma.

50 assays100Tests100 tests

Related Pathways

    No related Items
paperclip

#33813145   2021/03/22 To Up

A simple electrochemical immunosensor based on worm-like platinum for highly sensitive determination of alpha-fetoprotein.

Alpha-fetoprotein (AFP) has become a specific tumor marker of primary liver cancer in clinical diagnosis. In this work, we prepared worm-like platinum (WL Pt) nanomaterial via chemical etching without organic solvents and ultra-high temperature. Due to its small particle size and the formation of surface vacancies during the etching process, it had a large specific surface area, and thus exhibited superior electrocatalytic activity for the reduction of hydrogen peroxide. Combining the signal amplification based on hydrogen peroxide reduction and the specific recognition of antigen with antibody, we constructed a simple label-free electrochemical immunosensor with a sandwich-like structure. The developed electrochemical immunosensor showed a wide linear range (0.0001-100 ng mL), a low detection limit (0.028 pg mL), good selectivity and stability. Further, the immunosensor was comparable with enzyme-linked immunosorbent assay (ELISA) and had a good accuracy for AFP detection in human serum samples proving the feasibility of potential application, which is expect to become one of the most promising method in early diagnosis and clinical analysis for liver cancer.
Shan-Shan Li, Yuan-Yuan Tan, Yan Zhang, Mingjun Liu, Aihua Liu

1487 related Products with: A simple electrochemical immunosensor based on worm-like platinum for highly sensitive determination of alpha-fetoprotein.

100ug Lyophilized100ug Lyophilized100tests1,000 tests100ug Lyophilized100ug Lyophilized100ug1mg100tests100ug Lyophilized96 tests

Related Pathways

paperclip

#33804983   2021/03/24 To Up

A Portable Microfluidic System for Point-of-Care Detection of Multiple Protein Biomarkers.

Protein biomarkers are indicators of many diseases and are commonly used for disease diagnosis and prognosis prediction in the clinic. The urgent need for point-of-care (POC) detection of protein biomarkers has promoted the development of automated and fully sealed immunoassay platforms. In this study, a portable microfluidic system was established for the POC detection of multiple protein biomarkers by combining a protein microarray for a multiplex immunoassay and a microfluidic cassette for reagent storage and liquid manipulation. The entire procedure for the immunoassay was automatically conducted, which included the antibody-antigen reaction, washing and detection. Alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA) and carcinoma antigen 125 (CA125) were simultaneously detected in this system within 40 min with limits of detection of 0.303 ng/mL, 1.870 ng/mL, and 18.617 U/mL, respectively. Five clinical samples were collected and tested, and the results show good correlations compared to those measured by the commercial instrument in the hospital. The immunoassay cassette system can function as a versatile platform for the rapid and sensitive multiplexed detection of biomarkers; therefore, it has great potential for POC diagnostics.
Nan Li, Minjie Shen, Youchun Xu

1008 related Products with: A Portable Microfluidic System for Point-of-Care Detection of Multiple Protein Biomarkers.

100μg100ug100ug0.1 mg10ìg0.1 mg5ml100ug Lyophilized100ug Lyophilized

Related Pathways

paperclip

#33709835   2021/03/12 To Up

Predictive value of quad serum markers for adverse pregnancy outcome in antiphospholipid antibody syndrome.

We investigated the validity of quad serum markers for the prediction of adverse pregnancy outcome (APO) in women with antiphospholipid antibody syndrome (APS).
Sir-Yeon Hong, Seo-Yeon Kim, Jin-Ha Kim, Jee-Youn Hong, Ji-Hee Sung, Suk-Joo Choi, Soo-Young Oh, Cheong-Rae Roh

1759 related Products with: Predictive value of quad serum markers for adverse pregnancy outcome in antiphospholipid antibody syndrome.

96T1 Set1 Set1 Set1 Set100ug4 Arrays/Slide8 Sample Kit1 Set1 Set1 Set

Related Pathways

paperclip

#33628599   // To Up

Diagnostic value of 5 serum biomarkers for hepatocellular carcinoma with different epidemiological backgrounds: A large-scale, retrospective study.

Hepatocellular carcinoma (HCC) is a lethal global disease that requires an accurate diagnosis. We assessed the potential of 5 serum biomarkers (AFP, AFU, GGT-II, GPC3, and HGF) in the diagnosis of HCC.
Dongming Liu, Yi Luo, Lu Chen, Liwei Chen, Duo Zuo, Yueguo Li, Xiaofang Zhang, Jing Wu, Qing Xi, Guangtao Li, Lisha Qi, Xiaofen Yue, Xiehua Zhang, Zhuoyu Sun, Ning Zhang, Tianqiang Song, Wei Lu, Hua Guo

2404 related Products with: Diagnostic value of 5 serum biomarkers for hepatocellular carcinoma with different epidemiological backgrounds: A large-scale, retrospective study.

50ml10 mg50ml50ul500ml500mg50mg

Related Pathways

paperclip

#33596694   // To Up

Combination treatment for advanced hepatocellular carcinoma with portal vein tumour thrombus: A case report.

We present a case of a 43-year-old man with advanced hepatocellular carcinoma (HCC) with portal vein tumour thrombus. Initially, transcatheter arterial chemoembolization (TACE) was performed. Although alpha-fetoprotein (AFP) levels decreased, circulating tumour DNA (ctDNA) levels showed an upward trend, and abdominal magnetic resonance imaging (MRI) showed that tumours in the portal vein had increased. Based on ctDNA profiling, apatinib and anti-programmed cell death protein 1 (anti-PD-1) antibodies and were sequentially administered. Approximately three months later, intrahepatic tumours had significantly diminished and AFP and ctDNA levels had reduced. The response was sustained at the 23-month follow-up and the patient was in good health. Combination treatment of TACE, apatinib and anti-PD-1 antibodies was effective, and profiling of ctDNA fragmentation may be beneficial in the therapeutic management of patients with HCC.
Jianrong Wang, Junxue Wang, Jianzhu Wang, Ziliang Qian, Wensheng Xu, Xiaofeng Hang

2864 related Products with: Combination treatment for advanced hepatocellular carcinoma with portal vein tumour thrombus: A case report.



Related Pathways